January 2020

Presentations

Ladiratuzumab Vedotin | Gastrointestinal Cancer | Abstract TPS469​

SGNLVA-005: Open-label, phase 2 study of ladiratuzumab vedotin (LV) for advanced aerodigestive tract malignancies